The latest news from academia, regulators
research labs and other things of interest
Posted: August 11, 2010
The Forschungszentrum Dresden-Rossendorf Chooses NanoSight to Characterize Magnetic Nanoparticles
(Nanowerk News) The Institute for Radiopharmacy at the Forschungszentrum Dresden-Rossendorf is using NanoSight's LM-20 nanoparticle characterization system to study magnetic nanoparticles for applications in cancer therapy.
The research team of Dr Holger Stephan is working to develop magnetic nanoparticles which can be applied in cancer therapy, preferably in combination with intracellular hyperthermia/ablation and endoradionuclide therapies. This requires nanoparticles to be very stable under physiological conditions and they should also avoid accumulation in the reticuloendothelial system.
Many techniques had been used to characterize the nanoparticles before Dr Stephan discovered the NanoSight system. These included Photon Correlation Spectroscopy (PCS), scanning electron microscopy (SEM) and ultra centrifugation. The NanoSight ability to track individual particles by the scattering of a laser beam has made the study of nanoparticle stability much more convenient. Nanoparticle Tracking Analysis, NTA, has been used to successfully follow the stability of different systems as a function of temperature in EDTA and different cell media.
There are three specific goals for measurement: First is to get information about the size distribution of nanoparticles and, more importantly, their stability under physiological relevant conditions, Next is to study the influence of nanoparticle surface modification on the size distribution finally to achieve structure-activity relationships for the nanoparticles on the cellular uptake behaviour (first step) and cancer tissue accumulation (second step).
Dr Stephan has described several advantages of the NanoSight LM-20 system. He says "the NanoSight provides reliable results on nanoparticles as small as 50nm. Sample handling and measurement is straightforward and experiments are performed more quickly than using PCS. The ability to work directly with relevant solutions removes another block to quickly understanding the behaviour of these magnetic nanoparticles and their ultimate use in treating cancers."
"Our goal," continues Dr Stephan "is to rewrite the medical paradigm, currently being "see and treat" and to make the future one of "detect and prevent." By working on the combining of different therapeutic methodologies, we will provide synergetic medical effectiveness."
NanoSight Limited, of Salisbury, UK, provides unique nanoparticle characterization technology. "Nanoparticle Tracking Analysis" (NTA) detects and visualizes populations of nanoparticles in liquids down to 10nm (material dependent) and measures the size of each particle from direct observations of diffusion. This particle-by-particle methodology goes beyond traditional light scattering techniques such as Dynamic Light Scattering (DLS), or Photon Correlation Spectroscopy (PCS), in providing high-resolution particle size distributions. Additionally NanoSight measures concentration and validates all data with video of particles moving under Brownian motion.
This characterization information is highly informative in understanding the more complex suspensions in biological systems, hence its wide application in development of drug delivery systems, viral vaccines, the study of toxicology of nanoparticles and their environmental fate and in biomarker detection. This real-time data also provides insight into the kinetics of protein aggregation and other time-dependent phenomena in a quantitative manner, at deeply sub-micron sizes.
NanoSight has more than 250 systems installed worldwide with users including BASF, BP, GlaxoSmithKline, Novartis, 3M Corp., Roche, Solvay and Unilever together with many universities and research institutes. There are currently 100+ third party papers citing NanoSight results, with this reference base growing very rapidly as NanoSight consolidates its key contribution to nanoparticle characterization. For more information, visit www.nanosight.com.